Jump to content



Recommended Posts

Bristol Myers acknowledged defeat withdrawing Optivo's indication in SCLC that has progressed after platinu-base chemo and at least on other line of therapy.\

The development came 2 years after the failure of 2 confirmatory studies, which were meant to turn Optivo's accelerated approval earned in 2018. 

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.